Adrenocortical Carcinoma and CT Assessment of Therapy Response: The Value of Combining Multiple Criteria
| Autor: | Martina Bertuletti, Luigi Grazioli, Salvatore Grisanti, Maria Carolina Balli, Filippo Vaccher, Guido A. M. Tiberio, Roberta Ambrosini, Deborah Cosentini, Marta Laganà, Marco Di Terlizzi, Alfredo Berruti, Luca Bottoni, Sandra Sigala |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Cancer Research medicine.medical_specialty Disease Response Concordance medicine.medical_treatment Computed tomography response criteria lcsh:RC254-282 RECIST 1.1 Article 03 medical and health sciences 0302 clinical medicine medicine adrenocortical carcinoma Adrenocortical carcinoma Progression-free survival Choi ACC Chemotherapy medicine.diagnostic_test business.industry computed tomography medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens 030104 developmental biology Therapy response Oncology tumor volume 030220 oncology & carcinogenesis Radiology business Progressive disease CT |
| Zdroj: | Cancers Volume 12 Issue 6 Cancers, Vol 12, Iss 1395, p 1395 (2020) |
| ISSN: | 2072-6694 |
| DOI: | 10.3390/cancers12061395 |
| Popis: | We evaluated tumor response at Computed Tomography (CT) according to three radiologic criteria: RECIST 1.1, CHOI and tumor volume in 34 patients with metastatic adrenocortical carcinoma (ACC) submitted to standard chemotherapy. These three criteria agreed in defining partial response, stable or progressive disease in 24 patients (70.5%). Partial response (PR) was observed in 29.4%, 29.4% and 41.2% of patients according to RECIST 1.1, CHOI and tumor volume, respectively. It was associated with a favorable prognosis, regardless of the criterion adopted. The concordance of all the 3 criteria in defining the disease response identified 8 patients (23.5%) which displayed a very good prognosis: median progression free survival (PFS) and overall survival (OS) 14.9 and 37.7 months, respectively. Seven patients (20.6%) with PR assessed by one or two criteria, however, still had a better prognosis than non-responding patients, both in terms of PFS: median 12.3 versus 9.9 months and OS: 21 versus 12.2, respectively. In conclusions, the CT assessment of disease response of ACC patients to chemotherapy with 3 different criteria is feasible and allows the identification of a patient subset with a more favorable outcome. PR with at least one criterion can be useful to early identify patients that deserve continuing the therapy. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|